Skip to main content
PIPELINE > TRIAL OVERVIEW

Trial Information
Molecule Overview
BTK Inhibitor
Pirtobrutinib
Phase
2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
Related Resources:
Molecule Overview Trial Enrollment
BRUIN CLL-211
Key Inclusion Criteria
  • Confirmed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and in need of treatment defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria
  • Received at least 1, but not more than 3, lines of prior treatment for CLL/SLL
  • Received a covalent Bruton's tyrosine kinase (BTK) inhibitor
  • Capable of swallowing oral study medication
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
Key Exclusion Criteria
  • Received prior BTK degrader and a noncovalent BTK inhibitor treatment
  • History of ≥Grade 3 bleeding due to treatment with a BTK inhibitor
  • Known or suspected Richter's transformation
  • Known or suspected history of central nervous system involvement by CLL/SLL
  • Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:
    • Nonmelanoma skin cancer or lentigo malignant melanoma
    • Cervical carcinoma in situ
    • Localized prostate cancer undergoing active surveillance
    • Localized (for example, lymph node negative) breast cancer with no evidence of active disease for >3 years. Individual may be receiving adjuvant hormonal therapy
a
Pirtobrutinib is administered orally.
For information on trial enrollment, locations, and more, call 1-800-545-5979.
REQUEST A MEDICAL SCIENCE LIAISON

or visit www.clinicaltrials.gov for more information on this trial